TY  - JOUR
A1  - Bothe, Sebastian
A1  - Hänzelmann, Petra
A1  - Böhler, Stephan
A1  - Kehrein, Josef
A1  - Zehe, Markus
A1  - Wiedemann, Christoph
A1  - Hellmich, Ute A.
A1  - Brenk, Ruth
A1  - Schindelin, Hermann
A1  - Sotriffer, Christoph
T1  - Fragment screening using biolayer interferometry reveals ligands targeting the SHP-motif binding site of the AAA+ ATPase p97
JF  - Communications Chemistry
N2  - Biosensor techniques have become increasingly important for fragment-based drug discovery during the last years. The AAA+ ATPase p97 is an essential protein with key roles in protein homeostasis and a possible target for cancer chemotherapy. Currently available p97 inhibitors address its ATPase activity and globally impair p97-mediated processes. In contrast, inhibition of cofactor binding to the N-domain by a protein-protein-interaction inhibitor would enable the selective targeting of specific p97 functions. Here, we describe a biolayer interferometry-based fragment screen targeting the N-domain of p97 and demonstrate that a region known as SHP-motif binding site can be targeted with small molecules. Guided by molecular dynamics simulations, the binding sites of selected screening hits were postulated and experimentally validated using protein- and ligand-based NMR techniques, as well as X-ray crystallography, ultimately resulting in the first structure of a small molecule in complex with the N-domain of p97. The identified fragments provide insights into how this region could be targeted and present first chemical starting points for the development of a protein-protein interaction inhibitor preventing the binding of selected cofactors to p97.
KW  - fragment screening
KW  - AAA+ ATPase p97
KW  - biosensor
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300821
VL  - 5
IS  - 1
ER  - 
TY  - JOUR
A1  - Drechsler, Christiane
A1  - Schmiedeke, Benjamin
A1  - Niemann, Markus
A1  - Schmiedeke, Daniel
A1  - Krämer, Johannes
A1  - Turkin, Irina
A1  - Blouin, Katja
A1  - Emmert, Andrea
A1  - Pilz, Stefan
A1  - Obermayer-Pietsch, Barbara
A1  - Wiedemann, Frank
A1  - Breunig, Frank
A1  - Wanner, Christoph
T1  - Potential role of vitamin D deficiency on Fabry cardiomyopathy
JF  - Journal of Inherited Metabolic Disease
N2  - Patients with Fabry disease frequently develop left ventricular (LV) hypertrophy and renal fibrosis. Due to heat intolerance and an inability to sweat, patients tend to avoid exposure to sunlight. We hypothesized that subsequent vitamin D deficiency may contribute to Fabry cardiomyopathy. This study investigated the vitamin D status and its association with LV mass and adverse clinical symptoms in patients with Fabry disease. 25-hydroxyvitamin D (25[OH]D) was measured in 111 patients who were genetically proven to have Fabry disease. LV mass and cardiomyopathy were assessed by magnetic resonance imaging and echocardiography. In cross-sectional analyses, associations with adverse clinical outcomes were determined by linear and binary logistic regression analyses, respectively, and were adjusted for age, sex, BMI and season. Patients had a mean age of 40 ± 13 years (42 % males), and a mean 25(OH)D of 23.5 ± 11.4 ng/ml. Those with overt vitamin D deficiency (25[OH]D ≤ 15 ng/ml) had an adjusted six fold higher risk of cardiomyopathy, compared to those with sufficient 25(OH)D levels >30 ng/ml (p = 0.04). The mean LV mass was distinctively different with 170 ± 75 g in deficient, 154 ± 60 g in moderately deficient and 128 ± 58 g in vitamin D sufficient patients (p = 0.01). With increasing severity of vitamin D deficiency, the median levels of proteinuria increased, as well as the prevalences of depression, edema, cornea verticillata and the need for medical pain therapy. In conclusion, vitamin D deficiency was strongly associated with cardiomyopathy and adverse clinical symptoms in patients with Fabry disease. Whether vitamin D supplementation improves complications of Fabry disease, requires a randomized controlled trial.
KW  - Fabry patient
KW  - urinary protein excretion
KW  - hypertrophic cardiomyopathy
KW  - renal fibrosis
KW  - left ventricular mass
KW  - LV mass
KW  - diabetic mouse
KW  - septal hypertrophy
KW  - Fabry nephropathy
KW  - cardiac hypertrophy
KW  - cornea verticillata
KW  - enzyme replacement therapy
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-132102
VL  - 37
IS  - 2
ER  -